Introduction {#Sec1}
============

Premature infants, especially very low birth weight (VLBW) infants (\<1500 g), are a group at high risk of infectious diseases in neonatal intensive care units (NICUs), and such infections impose a great socioeconomic burden and account for 23% of total newborn health care costs.^[@CR1]--[@CR3]^ Ventilator-associated pneumonia (VAP), a frequent and severe complication in premature infants on mechanical ventilation, is considered the second most common infectious disease in the NICU, ranked behind central line-associated bloodstream infections.^[@CR4],[@CR5]^ Considering the longer hospital stay and rising medical cost, prophylaxis of VAP is required.

Low immune function in VLBWs is a high-risk factor for VAP.^[@CR6],[@CR7]^ The smaller the gestational age, the lower the birth weight and the higher incidence of VAP will be, suggesting that immune function and lung maturity have a closer relationship with VAP.^[@CR7],[@CR8]^ Recent studies found that immunoglobulins are vital to reducing the risk of ventilator-related infections,^[@CR9]^ and there are considerable immunoglobulins in human milk.

Human milk is recognized as the most beneficial form of nutrition for infants, and the concentration of immune factors is much higher in colostrum than in mature milk.^[@CR10]^ Colostrum, secreted 2 to 3 days after birth, is rich in immunoglobulins (e.g., IgG, IgA, IgM and lactoferrin), of which secretory IgA (SIgA) is the highest in all exocrine fluids.^[@CR10]^ It has been shown that colostrum appears to lower the risk of late-onset sepsis, feeding intolerance, and other complications of preterm labor.^[@CR10],[@CR11]^

In critically ill adult patients, oropharyngeal administration of probiotics is capable of effectively alleviating oral contamination and reducing the incidence of VAP, suggesting that the oropharyngeal mucosa can effectively stimulate immune activation.^[@CR12]--[@CR14]^ Recent studies on oral and pharyngeal colostrum administration in preterm infants have revealed a rise in the number of immune components in preterm infants. Based on this evidence, NICUs have begun colostrum therapy for premature infants to further enhance immune protection.^[@CR15],[@CR16]^

Oropharyngeal colostrum (OC) is a novel feeding strategy to prevent complications of prematurity. Previous studies revealed that the OC procedure is easy to implement and does not require enteral feeding.^[@CR16]^ The breast milk required is small in amount for the baby to swallow. A small amount of milk (usually 0.2 mL divided into two cheeks) is placed on the mucous membrane of the mouth for absorption. Sterile cotton swabs or oral applicators are used for each application of human milk.^[@CR17]^ Colostrum contacts the mouth and oropharyngeal pouch and produces immune protection and stimulation of oropharyngeal receptors by the abundant anti-inflammatory and pro-inflammatory cytokines detected in the mother's colostrum and milk. Gastrointestinal movement, secretion, and absorption capacity are enhanced.^[@CR18]^

Previous studies have suggested that OC can effectively increase the immune factors of premature infants and has major implications for preventing complications of prematurity.^[@CR19]--[@CR29]^

From the perspective of the author, this meta-analysis focused on investigating colostrum's connection with the clinical complications of VLBW infants (\<32 weeks gestation and/or \<1500 g birth weight) as well as the clinical and economic benefits. Accordingly, a meta-analysis and a systematic review were conducted to investigate whether VLBW infants can benefit from the administration of OC.

Methods {#Sec2}
=======

This meta-analysis of the existing literature was conducted in line with the Preferred Reporting Items for the guidelines of Meta-Analyses and Systematic Reviews.^[@CR30]^ The PRISMA checklist is shown in an additional file (see Additional file [1](#MOESM1){ref-type="media"}).

Literature search strategy {#Sec3}
--------------------------

The electronic literature databases were searched as follows: Embase, PubMed, Web of Science, and Cochrane Central Register of Controlled Trials from their date of inception to May 2019. The following search terms were used as keywords to identify all relevant studies: "oropharyngeal colostrum" or "colostrum" or "human milk" and "newborn" or "VLBW infant" or "low birth weight infant" or "premature infant" or "neonate." Related papers that were listed in the references and included these keywords were also examined for potentially qualified studies.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies with the following criteria were included:Type of trials: Randomized controlled trials (RCTs).Population: Preterm infants delivered at \<32 weeks gestation and/or \<1500 g birth weight.Intervention: Administration of OC to premature infants.Comparison: Placebo alone (saline) or no intervention.Outcome: Primary outcomes (e.g., VAP, necrotizing enterocolitis (NEC), bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), proven sepsis, clinical sepsis, late-onset sepsis, and death) and secondary outcomes (e.g., length of stay and time of full enteral feeding).

Studies with the following criteria were excluded:Not published in English.Not published as original articles.Uncontrolled, pseudorandomized, retrospective studies, reviews, systematic reviews, meta-analyses, case reports, letters, correspondences, comments, or editorials.Including no data on clinical outcomes in the premature infant.Full text of the article not available.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Two reviewers assessed the data from the included studies. Through discussion, the differences between the two reviewers were resolved. The extracted data included the study design, the source of patients, publication year, the author, and detailed clinical outcomes (VAP, NEC, BPD, ROP, death, length of stay, time of full enteral feeding, proven sepsis, clinical sepsis, late-onset sepsis) stratified by OC. Evaluation of research quality was based on six basic criteria of the Cochrane Bias Risk Assessment Tool: selective outcome reporting, incomplete outcome data, blinding of outcome assessors, allocation concealment, sequence generation, and other bias sources.^[@CR31]^

Statistical analysis {#Sec6}
--------------------

Every statistical analysis was conducted by adopting the odds ratio (OR), and Review Manager (RevMan, version 5.3.5) with 95% confidence intervals (CIs) was used to assess the effect of OC and the incidence of diseases. Odds ratios (ORs) or mean differences (MDs) with 95% CIs were employed to assess the association between the clinical outcomes and OC administration for categorical or continuous variables, respectively. Heterogeneity in the study was assessed by the *I*^2^ tests and Cochran's *Q* statistic.^[@CR32]^ The random-effects model was adopted when heterogeneity was significant (*I*^2^ \> 50%). Otherwise, the model with settled effects was adopted. Sensitivity analysis was guided by dropping out every study in a sequential way. The strategies of Begg and Egger were used to assess publication bias,^[@CR33]^ through which an assessment of funnel-plot asymmetry was achieved.

Results {#Sec7}
=======

Study characteristics {#Sec8}
---------------------

In our literature search, 204 potentially relevant citations were identified. Of these, 12 references that might be included in the meta-analysis were retrieved for further consideration.^[@CR15],[@CR19]--[@CR29]^ However, three of these 12 items were retrospective studies,^[@CR15],[@CR19],[@CR20]^ and one^[@CR21]^ was a non‐randomized interventional study. Therefore, eight RCTs finally met our criteria and were suitable for inclusion in the meta-analysis.^[@CR22]--[@CR29]^ The article selection is summarized in Fig. [1](#Fig1){ref-type="fig"}. Three studies were conducted in the United States, and the other five studies were conducted in Egypt, Brazil, China, India, and Korea. All the studies were RCTs. The sample size was 682 in total (OC group: 332; non-OC group: 350). Three studies^[@CR23],[@CR24],[@CR27]^ achieved a double-blind controlled design, and other trials were single blinded. The included studies' features are listed in Table [1](#Tab1){ref-type="table"}, and each included study's particular quality scores are shown in Fig. [2](#Fig2){ref-type="fig"}. The characteristics of feeding are listed in Table [2](#Tab2){ref-type="table"}.Fig. 1RCT, randomized controlled trial.The flow chart of article selection.Table 1Main characteristics of the included studies.Author, ref.CountryNa (OC/non-OC)PopulationInterventionVentilation baseline (OC vs. non-OC)Statistically significantNon-statistically significantAbd-Elgawad et al.^[@CR22]^Egypt100/100 NICUPreterm infants delivered at \<32 weeks gestation and \<1500 g birth weight who had sufficient supply of mother's milk to cover the whole duration of enteral feeding0.2 mL colostrum/oropharyngeal pouch, tongue, and cheeks/every 2--4 h immediately after randomizationConventional ventilation32% vs. 37%*P* = 0.55Duration of mechanical ventilation,VAP, time of full enteral feeding, time of full oral feeding, average weight gain, length of hospital stayCulture-positive nosocomial sepsis, suspected nosocomial sepsis, NEC, BPD, mortalityFerreira et al.^[@CR23]^Brazil47/66 NICUBirth weight \<1500 g and gestational age \<34 week's gestation0.2 mL colostrum/infant's mouth along the right buccal mucosal tissue/every 2 h over a period of 48 hMechanical ventilation day2 (0--5) vs. 2 (0--7) days*P* = 0.75---Late-onset, sepsis, NEC, IVH, ROP, BPD, deathZhang et al.^[@CR24]^China32/32 NICUBirth weight ≤1500 g0.2 mL of colostrum/infant's mouth along one side of the cheek over a period of at least 20 s/every 4 h for 7 days---Days reaching full enteral feeding, lactoferrin in salivaNEC, clinical sepsis, proven sepsis, days starting oral feedingSharma et al.^[@CR25]^India59/59 NICUBirth weight \<1250 g and/or gestational age \<30 weeks and availability of maternal colostrum0.2 mL colostrum/infant's mouth/started after 24 h of postnatal life/every 2 h for the next 72 hInvasive ventilation27.1% vs. 31%*P* = 0.70Duration of hospital stayNEC, late-onset sepsis, blood culture-positive sepsis, VAP, days to reach full enteral feed, BPD, mortalityRomano et al.^[@CR26]^USA48/51 NICUBirth at \<32 weeks completed gestation0.2 mL colostrum/beginning in the first 48 h of life/every 6 h for 5 days---Days to dischargeNEC, days to 100 mL/kg per dayLee et al.^[@CR27]^Korean21/21 NICUNeonates born before 28 weeks gestation0.2 mL colostrum/beginning at 48 to 96 h after birth/buccal mucosa/every 3 h for 72 consecutive hoursMechanical ventilation58% vs. 75%*P* = NSClinical sepsis, total antibiotic days, postnatal days to reach full feedingNEC, BPD, VAP, proven sepsis, IVH, hospital stay, deathGlass et al.^[@CR28]^USA17/13 NICUVLBW infants, \<1500 g0.2 mL of mother's colostrum/oral mucosa/every 3 h from day of life (DOL) 2 until DOL 7Invasive mechanical ventilation47% vs. 62%*P* = NS---Suspected sepsis, culture-positive sepsis, NECRodriguez^[@CR29]^USA8/8 NICUBirth weight \<1000 g and/or gestation \<28 weeks0.2 mL colostrum/alongside the buccal mucosal tissue, and directing it posteriorly towards the oropharynx/started within 48 h of life/carried out every 2 h over a treatment period of 48 consecutive hours---Time to full enteral feedsTime to full per oral feeds, length of hospital stay, corrected gestational age at discharge, respiratory distress syndrome, bacteremia, pneumonia, NEC, chronic lung disease, death*OC* oropharyngeal colostrum, *VAP* ventilator-associated pneumonia, *NICU* neonatal intensive care unit, *VLBW* very low birth weight infant, *NEC* necrotizing enterocolitis, *BPD* bronchopulmonary dysplasia, *IVH* intraventricular hemorrhage, *ROP* retinopathy of prematurity, *NS* no significance.Fig. 2Risk of bias assessment.**a** Authors' judgments about each risk of bias item for each included study. **b** Authors' judgments about each risk of bias item presented as percentages across all included studies.Table 2Characteristics of feeding.Author, ref.Feeding typeDifference of feedingOCNon-OCContract by*P* valueAbd-Elgawad et al.^[@CR22]^Artificial milk formulaArtificial milk formulaCumulative % of breast milk volume to total milk volume (%)NSBreast milk (58%)Breast milk (60%)Zhang et al.^[@CR24]^FormulaFormula------Mothers' human milkMothers' human milkRomano et al.^[@CR26]^Expressed breast milk (69%)Expressed breast milk (71%)Type of feeds initial and at dischargeNSDonor breast milk (29%)Donor breast milk (27%)Formula (2%)Formula (2%)Lee et al.^[@CR27]^Breast milk (20%)Breast milk (25%)Feeding type during the protocol and for 2 weeks after birthNSPreterm formula (46%)Preterm formula (46%)Mixed (17%)Mixed (13%)None (17%)None (17%)Glass et al.^[@CR28]^---Amount of breast milk on day 7 and 14 daysNS*NS* no significance.

Ventilator-associated pneumonia {#Sec9}
-------------------------------

Of the eight studies, three reported VAP in the included infants. The aggregated results of these three studies suggested that low birth weight infants with OC administration presented a noticeable reduction in the incidence of VAP (OR = 0.39, 95% CI: 0.17--0.88, *P* = 0.02) (Fig. [3](#Fig3){ref-type="fig"}), and the test result for heterogeneity was mild (*P* = 0.26, *I*^2^ = 26%).Fig. 3Oropharyngeal colostrum was associated with a significantly reduced incidence of VAP, and a potential significance of NEC.Forest plot for the meta-analysis of the incidence of **a** ventilator-associated pneumonia (VAP) and **b** necrotizing enterocolitis (NEC).

Necrotizing enterocolitis and bronchopulmonary dysplasia {#Sec10}
--------------------------------------------------------

All eight studies obtained data regarding NEC, in which the differences were of potential statistical significance (OR = 0.51, 95% CI: 0.26--0.99, *P* = 0.05), and the test result for heterogeneity was ascertained to be non-significant (*P* = 0.60, *I*^2^ = 0%). Four studies^[@CR19],[@CR21],[@CR23],[@CR25]^ suggested data on BPD, and the different points in BPD were not statistically significant (OR = 0.77, 95% CI: 0.48--1.24, *P* = 0.28).

Death {#Sec11}
-----

Five studies^[@CR22],[@CR23],[@CR25],[@CR27],[@CR29]^ obtained data on death, and the analysis results suggested great statistical trends (OR = 0.60, 95% CI: 0.34--1.08, *P* = 0.09). The findings revealed that OC was associated with a decrease in mortality. However, the results were of no statistical significance.

Proven sepsis, clinical sepsis, and late-onset sepsis {#Sec12}
-----------------------------------------------------

Proven sepsis was defined as clinical sepsis plus biologic markers of systemic inflammatory response syndrome (altered leukocyte count, C-reactive protein \>12 mg/L) and positive blood culture. The effect of OC on proven sepsis in premature infants was assessed according to seven trials,^[@CR22]--[@CR28]^ and the heterogeneity was ascertained to be non-significant (*P* = 0.97, *I*^2^ = 0%). Although the results were not statistically significant, we still observed a decreasing trend of proven sepsis (OR = 0.64, 95% CI: 0.40--1.01, *P* = 0.06).

Clinical sepsis was defined as clinical signs of infection with antibiotic treatment for over three days.^[@CR34]^ Four studies^[@CR22],[@CR24],[@CR27],[@CR28]^ presented data on clinical sepsis, exhibiting moderately significant statistical heterogeneity between studies (*P* = 0.04, *I*^2^ = 63%). However, the difference in clinical sepsis was not statistically significant (OR = 0.54, 95% CI: 0.19--1.54, *P* = 0.25). Three studies^[@CR23],[@CR25],[@CR26]^ showed data on late-onset sepsis, and the different points were not statistically significant (OR = 0.71, 95% CI: 0.40--1.27, *P* = 0.25). All the results are listed in Table [3](#Tab3){ref-type="table"}.Table 3Association of oropharyngeal colostrum with clinical outcomes.CategoriesVariables*N*^a^Case^b^Pooled dataHeterogeneityPresentAbsentOR/MD*P* value*I*^2^ (%)*Ph*Late-onset sepsisYes vs. no31541750.71 \[0.40, 1.27\]0.2500.80Clinical sepsisYes vs. no41681650.54 \[0.19, 1.54\]0.25630.04Proven sepsisYes vs. no73223400.64 \[0.40, 1.01\]0.0600.97NECYes vs. o83313460.51 \[0.26, 0.99\]0.0500.60BPDYes vs. no42302480.77 \[0.48, 1.24\]0.2850.37VAPYes vs. o31831820.39 \[0.17, 0.88\]**0.02**260.26DeathYes vs. no52392540.60 \[0.34, 1.08\]0.0900.68Length of stayDays6285305−4.68 \[−12.52, 3.15\]0.2495\<0.001Time of full enteral feedingDays7286299−2.66 \[−4.51, −0.80\]**0.005**87\<0.001*OR* odds ratio, *MD* mean difference, *95% CI* 95% confidence interval, *P* *p* value of pooled HR; *I*^2^ value of *X*^2^ based *I*^2^ statistics, *Ph* *p* value of heterogeneity test.^a^Numbers of studies included in the meta-analysis.^b^Number of patients of included studies.The bold values are statistically significant.

Length of stay {#Sec13}
--------------

Overall, there were six studies covering 331 infants investigating the intervening effect of OC on length of stay.^[@CR22],[@CR23],[@CR25]--[@CR27],[@CR29]^ However, the results were not statistically significant (MD = −4.68, 95% CI: −12.52 to 3.15), *P* = 0.24).

Time of full enteral feeding {#Sec14}
----------------------------

Seven studies^[@CR22]--[@CR25],[@CR27]--[@CR29]^ investigated whether OC can reduce the time of full enteral feeding, and the evidence of significant heterogeneity was obvious (*P* \< 0.001, *I*^2^ = 87%). The results showed that OC indeed significantly shortened the length of full enteral feeding time (MD = −2.66, 95% CI: −4.51 to −0.80, *P* = 0.005) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Oropharyngeal colostrum significantly shorten the length of full enteral feeding time, and a decreased trend of proven sepsis and death.Forest plot for the meta-analysis of **a** proven sepsis, **b** time of full enteral feeding, and **c** death.

Discussion {#Sec15}
==========

Our meta-analysis suggested that OC was associated with a significant reduction in the incidence of VAP and shortened the full enteral feeding days, with a potential significance of reducing the incidence of NEC and a trend toward downregulating the ICU mortality and the incidence of proven sepsis. However, the results revealed no statistically significant change in the length of ICU stay, BPD, ROP, or late-onset sepsis. The clinical evidence regarding the strengths of OC administration in VLBW infants has great implications for neonatal infection-related diseases. We could further concentrate our interest on the economic and clinical benefits of OC.

Previous studies^[@CR16],[@CR17]^ demonstrated the safety and feasibility of oral care with colostrum. The whole process was very safe, and there were no adverse events associated with this procedure. A sterile cotton swab was dipped in milk (for which the estimated amount of milk was 0.2 mL), and the cotton was placed in the infant's mouth close to the oropharynx. The transfer of sIgA and lactoferrin was evident in the urine and tracheal aspirates.

Lee et al.^[@CR27]^ and Rodriguez's^[@CR29]^ studies observed increased levels of circulating immune-protective factors (IgA, IgM, and lactoferrin) in urine and saliva and an inhibition of the secretion of pro-inflammatory cytokines of extremely premature infants submitted to colostrum oropharyngeal administration, directly proving that colostrum can increase neonatal immune factors and promote immunity.

It is generally known that the occurrence of VAP in premature infants is largely attributed to the immaturity of the immune system. In addition, a recent meta-analysis of the risk factors for VAP in neonates reported that low birth weight, prematurity, and parenteral nutrition were independent risk factors for VAP development.^[@CR7]^

The major findings of our meta-analysis evidenced the protective factors of oral colostrum against the development of VAP. There are many risk factors affecting the occurrence of VAP, among which one of the most important factors is the duration of mechanical ventilation.^[@CR7]^ We summarized the baseline risk for VAP in Table [1](#Tab1){ref-type="table"}, and the baselines of mechanical ventilation in the intervention and control groups were consistent. As an outcome indicator, Abd-Elgawad's study^[@CR22]^ showed that colostrum could significantly shorten the length of mechanical ventilation, which indirectly proved our point. Although we would like to extract more data on mechanical ventilation for deeper discussion, the lack of raw data in the article is our main difficulty, and it appears that most articles have not shifted their focus to the benefits of oral colostrum in premature infants with mechanical ventilation. Thibeau's study,^[@CR15]^ which we excluded because it is a retrospective study, directly investigated human milk and mechanical ventilation-related pneumonia, and there were no statistically significant differences. Since this study is not an RCT, the evidence is not very strong. Thus, we expect that more RCTs will be conducted on the relationship between VAP and colostrum.

NEC is a devastating intestinal inflammatory disease that can cause necrosis and perforation of the intestinal epithelium, with significant morbidity and mortality.^[@CR35],[@CR36]^ The prevention of NEC has become one of the most important topics of interest to researchers. In our meta-analysis, we found that intervention with OC can potentially reduce the occurrence of NEC (OR = 0.51, 95% CI: 0.26--0.99, *P* = 0.05). The *p* value is exactly equal to 0.05, and the confidence interval of the OR did not include 1, so we considered the result as potentially statistically significant. Although the pathophysiology of NEC is still not completely understood, recent research shows that maternal IgA protects against the development of NEC in preterm infants.^[@CR37]^ Colostrum is rich in immunoglobulins (e.g., IgG, IgA, IgM, and lactoferrin), of which SIgA is the highest in all exocrine fluids.^[@CR10]^ This also reasonably explains our results. Although the incidence of NEC was not statistically significant in the eight articles included, it was observed that the intervention group had a slight downward trend in each study, which may also be the reason for our potential statistical significance. Hence, we still need larger sample sizes of RCTs to continue to confirm the preventive effect of OC.

However, the incidence of sepsis, an immune-related high-risk neonatal disease (proven sepsis, clinical sepsis, and late-onset sepsis), was not statistically significant. We believe there are two possible reasons: first, Moreno's study^[@CR21]^ suggested that the sIgA of the colostrum group continued to increase over the 30 days of the observation period and was higher than that of the control group, while the lactoferrin content decreased after reaching its peak at 15 days. This reveals that the stimulating effect of colostrum on lactoferrin is not persistent. Previous studies revealed that low neonatal IgA levels were a risk factor for VAP,^[@CR38]^ and lactoferrin levels were associated with sepsis.^[@CR39]^ This can explain why in this meta-analysis, the occurrence of VAP was statistically significant, and sepsis only displayed a downward trend. Second, colostrum contact between the oropharyngeal mucosa and this fluid may have immunomodulatory effects resulting in a decrease in inflammation. The non-statistical significance of colostrum administration for sepsis may indicate that colostrum has an upregulating effect on the immune function of newborns, but may overexaggerate the downregulatory ability of inflammation. In this regard, colostrum administration may facilitate the prevention of VAP. Although we just found that OC was associated with a trend toward downregulating proven sepsis, we believe that low birth weight infants with proven sepsis may benefit from OC, so we hope that future studies will pay more attention to this part of the population and finally obtain a more certain answer.

It was found that OC administration significantly reduced the time to reach full enteral feeding, which agrees with five studies.^[@CR22],[@CR24],[@CR27],[@CR29]^ Such a finding is of great implication, since it shows that early enteral feeding of breast milk has a long-term beneficial effect on intestinal atrophy, lowering the risk of local inflammation, feeding intolerance, NEC, and hospital infection.^[@CR16]^ Accordingly, colostrum administration to preterm infants who cannot be fed intestinally may be a potential immunotherapy for VLBW infants.

In addition, we need to attach importance to the feeding type, breast milk consumption, and duration of breastmilk feeding. Five articles mentioned feeding strategies for oral colostrum administration and breast milk intake between the intervention and control groups (Table [2](#Tab2){ref-type="table"}). Although there was no significant difference in breast milk intake, the breast milk consumption in the control group was slightly higher than that in the intervention group, indicating that OC can achieve better clinical outcomes with a smaller amount, which is a good result.

Until now, two meta-analyses, namely, Garg's^[@CR40]^ and Panchal's^[@CR41]^ studies, have investigated the intervention of OC therapy. In fact, both our study and previous meta-analysis have analyzed the clinical outcome of NEC and BPD and have demonstrated that the full time of enteral feeding is associated with OC. However, there are also some differences between our study and the previous meta-analysis. Our study included a total of eight high-quality RCTs with 670 patients, as opposed to the previous meta-analysis. In addition, the present study showed that OC was associated with a significantly reduced incidence of VAP, which no previous meta-analysis has reported before. The lung and immune system of VLBW infants are immature, and a longer mechanical ventilation time will lead to higher VAP incidence, followed by higher mortality and a longer hospital stay. In consideration of this population of premature infants, early prevention with OC is very effective. This was also the main focus of our meta-analysis. We paid more attention to whether the routine use of OC therapy could protect the lungs of premature infants with mechanical ventilation from VAP.

There are several limitations of the present meta-analysis. First, only three articles mentioned VAP, although the results indicated statistical significance, the strengths of oral colostrum for VAP still require more attention, and more RCTs are required to confirm this view further. Second, three studies produced bar charts presenting the levels of IgA and lactoferrin in serum and urine, whereas these studies were not analyzed because there were no original data. Obviously, large RCTs are required to address the potential immunological benefits of OC.

Conclusions {#Sec16}
===========

According to the results of the pooled analysis of the currently available data, OC indeed significantly reduced the frequency of VAP and full enteral feeding days in the NICU. Furthermore, OC is safe and feasible; the therapy process displays no side effects and does not require considerable costs. Overall, OC therapy is considered a cost-effective method for VLBW infants, and it is worthy of routine clinical application.
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